Literature DB >> 10547693

Transmissible spongiform encephalopathies in humans.

E D Belay1.   

Abstract

Creutzfeldt-Jakob disease (CJD), the first transmissible spongiform encephalopathy (TSE) to be described in humans, occurs in a sporadic, familial, or iatrogenic form. Other TSEs in humans, shown to be associated with specific prion protein gene mutations, have been reported in different parts of the world. These TSEs compose a heterogeneous group of familial diseases that traditionally have been classified as familial CJD, Gerstmann-Sträussler-Scheinker syndrome, or fatal familial insomnia. In 1996, a newly recognized variant form of CJD among young patients (median age, 28 years) with unusual clinical features and a unique neuropathologic profile was reported in the United Kingdom. In the absence of known CJD risk factors or prion protein gene abnormalities, the UK government concluded that the clustering of these cases may represent transmission to humans of the agent causing bovine spongiform encephalopathy. Additional epidemiologic and recent laboratory data strongly support the UK government's conclusion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547693     DOI: 10.1146/annurev.micro.53.1.283

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  24 in total

1.  Geographic difference of mortality of Creutzfeldt-Jakob disease in Japan.

Authors:  Yosikazu Nakamura; Makoto Watanabe; Kiwamu Nagoshi; Masahito Yamada; Hidehiro Mizusawa
Journal:  J Epidemiol       Date:  2007-01       Impact factor: 3.211

2.  Sporadic fatal insomnia in an adolescent.

Authors:  Jennifer L Blase; Laura Cracco; Lawrence B Schonberger; Ryan A Maddox; Yvonne Cohen; Ignazio Cali; Ermias D Belay
Journal:  Pediatrics       Date:  2014-02-02       Impact factor: 7.124

Review 3.  Prions are affected by evolution at two levels.

Authors:  Reed B Wickner; Amy C Kelly
Journal:  Cell Mol Life Sci       Date:  2015-12-28       Impact factor: 9.261

Review 4.  The design and application of fluorophore-gold nanoparticle activatable probes.

Authors:  Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Phys Chem Chem Phys       Date:  2011-03-07       Impact factor: 3.676

5.  Normal modes of prion proteins: from native to infectious particle.

Authors:  Abraham O Samson; Michael Levitt
Journal:  Biochemistry       Date:  2011-03-04       Impact factor: 3.162

6.  Gaucher disease and parkinsonism, a molecular link theory.

Authors:  Ehud Goldin
Journal:  Mol Genet Metab       Date:  2010-08-10       Impact factor: 4.797

Review 7.  Presenile dementia syndromes: an update on taxonomy and diagnosis.

Authors:  M D Greicius; M D Geschwind; B L Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

8.  Preclinical deposition of pathological prion protein in muscle of experimentally infected primates.

Authors:  Susanne Krasemann; Melanie Neumann; Markus Geissen; Walter Bodemer; Franz-Josef Kaup; Walter Schulz-Schaeffer; Nathalie Morel; Adriano Aguzzi; Markus Glatzel
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

Review 9.  Human prion diseases: surgical lessons learned from iatrogenic prion transmission.

Authors:  David J Bonda; Sunil Manjila; Prachi Mehndiratta; Fahd Khan; Benjamin R Miller; Kaine Onwuzulike; Gianfranco Puoti; Mark L Cohen; Lawrence B Schonberger; Ignazio Cali
Journal:  Neurosurg Focus       Date:  2016-07       Impact factor: 4.047

10.  Human prion diseases in the United States.

Authors:  Robert C Holman; Ermias D Belay; Krista Y Christensen; Ryan A Maddox; Arialdi M Minino; Arianne M Folkema; Dana L Haberling; Teresa A Hammett; Kenneth D Kochanek; James J Sejvar; Lawrence B Schonberger
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.